| |
| |
|
| Insider
Information: |
Saks Samuel R |
| Relationship: |
Chief Medical Officer |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
598,762 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$40,099,992 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
598,762 |
|
|
| Total
Value |
$40,099,992 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Jazz Pharmaceuticals Inc |
JAZZ |
Chief Executive Office... |
2008-11-28 |
358,868 |
|
0 |
Premium* |
|
|
Tonix Pharmaceuticals Holding Corp |
TNXP |
Director |
2017-05-27 |
6,605 |
|
0 |
Premium* |
|
|
Auspex Pharmaceuticals, Inc. |
ASPX |
Chief Development Offi... |
2015-05-05 |
0 |
|
0 |
Premium* |
|
|
PDL Biopharma Inc |
PDLI |
Director |
2018-06-08 |
214,190 |
2015-09-14 |
0 |
Premium* |
|
|
Assertio Holdings Inc |
ASRT |
Director |
2016-05-12 |
5,099 |
2015-12-01 |
0 |
Premium* |
|
|
Protagonist Therapeutics, Inc |
PTGX |
Chief Medical Officer |
2021-02-26 |
14,000 |
2019-02-28 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| PTGX |
Protagonist Therapeutics,... |
Chief Medical Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
14,000 |
0 |
- |
|
| PTGX |
Protagonist Therapeutics,... |
Chief Development Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2018-06-08 |
4 |
A |
$2.76 |
$150,000 |
D/D |
54,348 |
214,190 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2017-06-09 |
4 |
A |
$2.47 |
$150,001 |
D/D |
60,729 |
159,842 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2017-05-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
750 |
6,605 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2017-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
750 |
5,855 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2016-06-21 |
4 |
B |
$2.00 |
$50,000 |
D/D |
25,000 |
63,550 |
2.39 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2016-06-21 |
4/A |
B |
$2.00 |
$25,000 |
D/D |
12,500 |
51,050 |
2.39 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2016-06-02 |
4 |
A |
$3.52 |
$250,001 |
D/D |
71,023 |
99,113 |
0 |
- |
|
| ASRT |
Assertio Holdings Inc |
Director |
– • – |
2016-05-12 |
4 |
D |
$17.52 |
$12,860 |
D/D |
(734) |
5,099 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2016-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
600 |
3,855 |
0 |
- |
|
| ASRT |
Assertio Holdings Inc |
Director |
– • – |
2015-12-01 |
4 |
D |
$19.00 |
$18,354 |
D/D |
(966) |
2,897 |
0 |
- |
|
| PDLI |
PDL Biopharma Inc |
Director |
– • – |
2015-09-14 |
4 |
A |
$5.34 |
$150,001 |
D/D |
28,090 |
28,090 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2015-07-17 |
4 |
B |
$7.50 |
$75,000 |
D/D |
10,000 |
32,550 |
2.39 |
- |
|
| ASPX |
Auspex Pharmaceuticals, I... |
Chief Development Officer |
• • – |
2015-05-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(67,338) |
0 |
0 |
- |
|
| ASPX |
Auspex Pharmaceuticals, I... |
Chief Development Officer |
• • – |
2014-02-10 |
4 |
B |
$12.00 |
$26,100 |
D/D |
2,175 |
63,839 |
2.81 |
- |
|
| ASPX |
Auspex Pharmaceuticals, I... |
Chief Development OfficerOffic |
• • – |
2014-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
61,664 |
|
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2013-08-14 |
4 |
B |
$0.00 |
$0 |
D/D |
5,883 |
22,550 |
2.31 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2013-04-26 |
4 |
OE |
$0.40 |
$66,667 |
D/D |
166,667 |
333,334 |
0 |
- |
|
| TNXP |
Tonix Pharmaceuticals Hol... |
Director |
– • – |
2013-01-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
166,667 |
|
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2008-11-28 |
4 |
A |
$1.28 |
$1,467 |
D/D |
1,146 |
358,868 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2008-05-30 |
4 |
A |
$6.50 |
$8,697 |
D/D |
1,338 |
357,722 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2008-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,793 |
356,384 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2007-11-30 |
4 |
A |
$13.18 |
$7,776 |
D/D |
590 |
347,591 |
0 |
- |
|
| JAZZ |
Jazz Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2007-11-14 |
4 |
B |
$13.38 |
$65,642 |
D/D |
4,900 |
347,001 |
2.81 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
